Recap: Xeris Pharmaceuticals Q2 Earnings

Shares of Xeris Pharmaceuticals XERS rose 3% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 50.78% over the past year to ($0.63), which beat the estimate of ($0.73).

Revenue of $2,027,000 up by 533.44% year over year, which beat the estimate of $1,860,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL: https://www.directeventreg.com/der/toRegistration.action

Price Action

Company's 52-week high was at $12.50

52-week low: $1.42

Price action over last quarter: Up 13.93%

Company Profile

Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. Its pipeline products are Diazepam, Pramlintide-Insulin, Self-Administered Glucagon, and others.